SG11202105403XA - Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof - Google Patents

Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof

Info

Publication number
SG11202105403XA
SG11202105403XA SG11202105403XA SG11202105403XA SG11202105403XA SG 11202105403X A SG11202105403X A SG 11202105403XA SG 11202105403X A SG11202105403X A SG 11202105403XA SG 11202105403X A SG11202105403X A SG 11202105403XA SG 11202105403X A SG11202105403X A SG 11202105403XA
Authority
SG
Singapore
Prior art keywords
granulocyte
factor receptor
stimulating factor
colony stimulating
macrophage colony
Prior art date
Application number
SG11202105403XA
Inventor
Pingxia Zhu
Ran Wu
Qingshuang Zhang
Qun Huang
Original Assignee
Staidson Beijing Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Staidson Beijing Biopharmaceuticals Co Ltd filed Critical Staidson Beijing Biopharmaceuticals Co Ltd
Publication of SG11202105403XA publication Critical patent/SG11202105403XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
SG11202105403XA 2018-11-27 2019-11-25 Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof SG11202105403XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018117581 2018-11-27
PCT/CN2019/120545 WO2020108423A1 (en) 2018-11-27 2019-11-25 Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof

Publications (1)

Publication Number Publication Date
SG11202105403XA true SG11202105403XA (en) 2021-06-29

Family

ID=70853745

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105403XA SG11202105403XA (en) 2018-11-27 2019-11-25 Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof

Country Status (13)

Country Link
US (1) US20230002496A1 (en)
EP (1) EP3902835A4 (en)
JP (2) JP7290725B2 (en)
KR (1) KR102655193B1 (en)
CN (2) CN116003597A (en)
AU (1) AU2019388584B2 (en)
BR (1) BR112021009709A2 (en)
CA (2) CA3120729A1 (en)
EA (1) EA202191470A1 (en)
PH (1) PH12021551195A1 (en)
SG (1) SG11202105403XA (en)
WO (1) WO2020108423A1 (en)
ZA (1) ZA202103596B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220281914A1 (en) * 2020-12-18 2022-09-08 Kiniksa Pharmaceuticals, Ltd. Protein compositions and methods for producing and using the same
CN116887856A (en) * 2022-01-20 2023-10-13 舒泰神（北京）生物制药股份有限公司 Antibody preparation for specifically recognizing granulocyte-macrophage colony stimulating factor receptor and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103641915B (en) * 2006-03-27 2017-04-12 医学免疫有限公司 Binding member for GM-CSF receptor
CN103193882B (en) * 2013-03-29 2014-11-05 浙江大学 Embryonic stem cell specific marker GM-CSFR alpha and application thereof

Also Published As

Publication number Publication date
EP3902835A4 (en) 2022-08-17
AU2019388584B2 (en) 2024-02-15
JP2023011887A (en) 2023-01-24
AU2019388584A1 (en) 2021-06-10
KR20210129631A (en) 2021-10-28
EA202191470A1 (en) 2021-09-07
CN116003597A (en) 2023-04-25
PH12021551195A1 (en) 2021-10-25
BR112021009709A2 (en) 2021-10-19
JP2022510171A (en) 2022-01-26
US20230002496A1 (en) 2023-01-05
EP3902835A1 (en) 2021-11-03
JP7290725B2 (en) 2023-06-13
WO2020108423A1 (en) 2020-06-04
CA3120729A1 (en) 2020-06-04
KR102655193B1 (en) 2024-04-04
ZA202103596B (en) 2022-04-28
CA3183309A1 (en) 2020-06-04
CN113348179A (en) 2021-09-03

Similar Documents

Publication Publication Date Title
IL284216B (en) Anti-transferrin receptor antibodies and uses thereof
IL276950A (en) Anti-cd73 antibodies and uses thereof
SG11202104969RA (en) Anti-nkg2a antibodies and uses thereof
EP3902837A4 (en) Monoclonal antibody against human interleukin-4 receptor alpha and use thereof
SG11202105885WA (en) Anti-claudin antibodies and uses thereof
ZA202006066B (en) Anti-hla-g antibodies and use thereof
IL284369A (en) Antibody against human il-4ra and use thereof
IL275826A (en) Anti-mct1 antibodies and uses thereof
IL281297A (en) Anti-npr1 antibodies and uses thereof
IL280922A (en) Anti-her2 polypeptides and methods of use thereof
SG11202009772PA (en) Anti-dll3 antibodies and uses thereof
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
ZA202103596B (en) Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof
IL282707A (en) Anti-tim-3 antibodies and their use
IL282708A (en) Anti-tim-3 antibodies and their use
IL276008A (en) Factor h potentiating antibodies and uses thereof
IL280321A (en) Anti-cxcr2 antibodies and uses thereof
IL277330A (en) Anti-il-27 antibodies and uses thereof
IL287690A (en) Anti-hvem antibodies and use thereof
IL283875A (en) Anti-il-27 antibodies and uses thereof
IL281202A (en) Anti-tnfrsf9 antibodies and uses thereof
IL277075A (en) Anti-phf-tau antibodies and uses thereof
IL276548A (en) Bcma-binding antibodies and uses thereof
IL283926A (en) Anti-alpha-synuclein antibodies and uses thereof
IL283890A (en) Anti-periostin antibodies and uses thereof